Audenz ((Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) Injection) - updated on RxList

Source: RxList - New and Updated Drug Monographs - Category: Drugs & Pharmacology Source Type: news

Related Links:

Ajay Kohli Vinay Kohli Chitra Chhabra Kohli By CHITRA CHHABRA KOHLI MD, AJAY KOHLI MD, and VINAY KOHLI MD, MBA With a doubling time of cases estimated between 3 days within the U.S. and about 6 days globally (at the time of this writing) COVID-19 is demonstrating its terrifying virulence as it spreads across the world. What’s perhaps equally terrifying, if not more, is the absence of a known cure or treatment plan for COVID-19. While there has been a lot of attention focused on Hydroxychloroquine and Azithromycin, there has been debate on the scientific validity of these treatment options, either as t...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: COVID-19 Patients Physicians Ajay Kohli Azithromycin convalescent plasma therapy coronavirus COVID-19 treatment hydroxychloroquine Pandemic Vinay Kohli Source Type: blogs
Basel, 27 March  2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) as well as two supplemental New Drug Applications (sNDA) for Xofluza® (baloxavir marboxil). The FDA accepted a NDA for a new formulation of Xofluza as one-dose granules for oral suspension (2 mg/mL), potentially offering a more convenient option for children and those who have difficulty swallowing. In addition, the application seeks approval of Xofluza for the treatment of acute uncomplicated influenza in otherwise healthy children aged one to l ess th...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Current influenza vaccines only confer protection against homologous viruses. We synthesized pulmonary surfactant (PS)–biomimetic liposomes encapsulating 2',3'-cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), an agonist of the interferon gene inducer STING (stimulator of interferon genes). The adjuvant (PS-GAMP) vigorously augmented influenza vaccine–induced humoral and CD8+ T cell immune responses in mice by simulating the early phase of viral infection without concomitant excess inflammation. Two days after intranasal immunization with PS-GAMP–adjuvanted H1N1 vaccine, strong cross-p...
Source: ScienceNOW - Category: Science Authors: Tags: Immunology, Microbiology, Online Only r-articles Source Type: news
Conclusions: Cross-reactive B cells of different germline origins could be activated and re-circulated by avian influenza virus. The HA stem epitopes targeted by the BnAbs, and the two Ab-encoding genes usage implied the VH1-69 and D3-9 are the ideal candidates triggered by influenza virus for vaccine development. PMID: 32131957 [PubMed - in process]
Source: Biomedical and Environmental Sciences : BES - Category: Biomedical Science Authors: Tags: Biomed Environ Sci Source Type: research
Source: RxList - New and Updated Drug Monographs - Category: Drugs & Pharmacology Source Type: news
“Everyone knows that pestilences have a way of recurring in the world,” observes Albert Camus in his novel The Plague. “Yet somehow we find it hard to believe in ones that crash down on our heads from a blue sky. There have been as many plagues as wars in history; yet plagues and wars always take people by surprise.” Camus was imagining a fictional outbreak of plague in 1948 in Oran, a port city in northwest Algeria. But at a time when the world is reeling from a very real microbial emergency sparked by the emergence of a novel coronavirus in Wuhan, central China, his observations are as pertinent a...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized 2019-nCoV health ideas Source Type: news
Audenz (Seqirus) is the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news
HOLLY SPRINGS, N.C., Feb. 3, 2020 /PRNewswire/ -- Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved Audenz™ (Influenza A (H5N1) Monovalent...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
Abstract The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the human population pose substantial economic and public health threats. Although antiviral drugs have some effect in treating influenza infection, vaccination is still the most effective intervention to prevent possible pandemic outbreaks. We have developed a novel H5 influenza vaccine to improve the world's pandemic preparedness. We produced a hemagglutinin (HA) of HPAI H5N1 virus A/Alberta/01/2014 (AB14) using both mammalian (m) and bacterial (b) expression systems. The purified recombinant proteins were formulated with...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract Newcastle disease virus (NDV) has been used as a vector in the development of vaccines and gene delivery. In the present study, we generated the thermostable recombinant NDV (rNDV) expressing the different forms of hemagglutinin (HA) of highly pathogenic avian influenza virus (HPAIV) H5N1 based on the full-length cDNA clone of thermostable TS09-C strain. The recombinant thermostable Newcastle disease viruses, rTS-HA, rTS-HA1 and rTS-tPAs/HA1, expressed the HA, HA1 or modified HA1 protein with the tissue plasminogen activator signal sequence (tPAs), respectively. The rNDVs displayed similar thermostability...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
More News: Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Drugs & Pharmacology | H5N1 | Influenza | Influenza Vaccine | Vaccines